General Condions of COVID-19 Proposal Call
Updated on: 22/06/2020
Proposal / Beamtime request (Public & Proprietary)
The COVID-19 operation mode is a reduced operation mode only accepting experiments correlated with research dedicated to aspects of fighting the COVID-19 pandemic.
To gain unbureaucraticly and fast access to beamtime, ALBA created a specific access mode called COVID-19 proposal call. The interested user can find details in the following Q&A links. For users from European Home Institutions, CalipsoPlus Funding will be available during this call.
- Proposal preparation Q&A
- Beamtime awarding process Q&A
- How is the beamtime processed Q&A
- End-of-run requirements Q&A
SCIENCE HIGHLIGHTS
A NEW KEY TARGET FOR THE TREATMENT OF PROSTATE CANCER |
MAPS SHOW HOW DRUGS REVERSE ALTERATIONS IN HEPATITIS C-INFECTED CELLS
|
SYNCHROTRON LIGHT UNVEILS NEW INSIGHTS ABOUT AMYOTROPHIC LATERAL SCLEROSIS
|
An international research lead by Institute of Biomedicine of the University of Barcelona (IBUB) and the Research Institute of the Hospital de la Santa Creu i Sant Pau (IIB Sant Pau) shows, for the first time, the three-dimensional structure of the homodimeric androgen receptor ligand-binding domain. In order to solve the 3D structure of the protein, X-ray diffraction analyses have been conducted at the XALOC beamline of the ALBA Synchrotron | The first 3D map of the interior of cells affected by the virus. Scientists at the Centro Nacional de Biotecnología of the CSIC (CNB-CSIC) and the ALBA Synchrotron have observed the alterations caused by the hepatitis C virus at the endoplasmic reticulum and mitochondria of infected cells. These malformations were reversed by treatment with the most common antiviral drugs for hepatitis C. | Synergetic combination of different imaging and spectroscopic synchrotron techniques performed in ALBA and APS (USA) has discovered new aspects about astrocytes cells of this neurodegenerative disease. Results, published in Analytical Chemistry, show significant differences between ALS and control astrocytes, including structural, chemical and macromolecular anomalies. |